Calendario›REGN›REGN7544 · ESTELLA

REGN7544 · ESTELLA

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

Ensayo de REGENERON PHARMACEUTICALS, INC. en Sepsis-Induced Hypotension (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

76

previstos

Centros

29

Fin del objetivo primario

feb 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en may 2025.

Qué mide

Cumulative vasopressor dose (Through 72 Hours) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital. The study is looking at several other research questions, including: * How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06608901), actualizada en may 2026.